Emme is a technology company.
Emme has raised $3.2M across 2 funding rounds.
Key people at Emme.
Emme has raised $3.2M in total across 2 funding rounds.
# High-Level Overview
Emme is a healthcare technology company focused on women's reproductive health, specifically addressing contraceptive adherence through connected hardware and software[2][4]. The company's flagship product, the Emme Smart Case and app, combines a patent-pending smart case with a personalized health tracking application to help women manage birth control more effectively[2][4].
Emme was founded in 2017 by Amanda French and Janene Fuerch, MD, with a mission to modernize women's reproductive health management[2][4]. The company operates as a lean, early-stage venture with fewer than 25 employees and estimated revenue under $5 million[2]. Rather than serving as an investment firm, Emme functions as a portfolio company itself—a healthcare technology startup addressing a specific pain point in women's health.
# Origin Story
The founding of Emme emerged from a moment of political concern. Co-founders Amanda French and Janene Fuerch decided to launch the company after the 2016 presidential election, driven by concerns about potential rollbacks in women's access to reproductive services and contraception[4]. This external catalyst crystallized their shared vision to create technology that would empower women to take control of their reproductive health.
The product concept itself addresses a well-documented clinical problem: medication non-adherence with oral contraceptives. Missed pills significantly reduce contraceptive efficacy, yet many women struggle with consistent daily adherence[4]. Recognizing this gap, French and Fuerch developed an integrated solution combining hardware and software. The company conducted a sold-out national beta, which demonstrated significant improvements in adherence rates and user confidence[4]. By 2020, Emme was preparing for full commercial launch after validating product-market fit through this beta phase[4].
# Core Differentiators
# Role in the Broader Tech Landscape
Emme operates within the digital health and femtech movement, a growing sector addressing historically underserved women's health needs. The company rides several converging trends: increasing smartphone penetration enabling connected health devices, growing consumer demand for reproductive autonomy, and venture capital's expanding focus on women's health innovation.
The timing is particularly significant given the regulatory and political uncertainty surrounding contraceptive access in the United States. By creating technology that maximizes the effectiveness of existing contraceptive methods, Emme provides value regardless of access barriers—women can optimize the birth control they already have. This positions the company at the intersection of healthcare technology, consumer wellness, and reproductive rights advocacy.
Emme's approach also reflects a broader shift in healthcare toward patient empowerment and data ownership. Rather than relying solely on provider-patient interactions, the smart case and app create a continuous feedback loop that gives women real-time insights into their reproductive health patterns.
# Quick Take & Future Outlook
As of the Stanford Biodesign interview (circa 2020), Emme was ramping production for commercial launch[4]. Looking forward, the company's growth will likely depend on several factors: achieving meaningful market penetration among women seeking improved contraceptive adherence, expanding the app's health tracking capabilities to address broader reproductive health concerns, and potentially exploring adjacent women's health applications beyond oral contraceptives.
The femtech sector has matured considerably since Emme's founding, with increased investor interest and clinical validation of digital health solutions. Emme's combination of hardware innovation, clinical credibility, and user-centered design positions it well within this landscape. Future success will hinge on translating beta validation into sustainable commercial adoption and potentially expanding beyond the contraceptive niche into a broader women's health platform.
Key people at Emme.
Emme has raised $3.2M in total across 2 funding rounds.
Emme's investors include Antler, Concrete Ventures, FJ Labs, Golden Ventures, Highline Beta Inc., iNovia Capital, Intel Capital, LOI Venture, Magnetic Ventures, Pioneer Fund, Practical Venture Capital, Structure Capital.
Emme has raised $3.2M across 2 funding rounds. Most recently, it raised $3.0M Seed in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2020 | $3.0M Seed | Antler, Concrete Ventures, FJ Labs, Golden Ventures, Highline Beta Inc., iNovia Capital, Intel Capital, LOI Venture, Magnetic Ventures, Pioneer Fund, Practical Venture Capital, Structure Capital, Dharmesh Shah, Frank Barbieri, Jevon MacDonald, Jim Pitkow, Mike Greenfield, Ramesh Haridas, Tom Newbold, Tom Williams | |
| Nov 1, 2019 | $200K Seed | 8VC, Activant Capital, Alumni Ventures, Banana Capital, Bascom Ventures, Baukunst, Cedar Capital Group, Kevin Ding, Founders Fund, Modern Venture Partners, Parkway VC, Tenaya Capital, Verified Capital, Alain Hanover, Alex Adelman, Rudy Gadre |
